Literature DB >> 24235959

Tuberculosis diagnosis in resource-limited settings: Clinical use of GeneXpert in the diagnosis of smear-negative PTB: a case report.

L Nakiyingi1, H Nankabirwa, M Lamorde.   

Abstract

BACKGROUND: The Xpert MTB/RIF test (GeneXpert) has recently been endorsed for use in resource-limited settings for the diagnosis of tuberculosis and drug resistant-tuberculosis. In resource-limited settings, GeneXpert has been used predominantly for research and there is little experience with its use in day-to-day management of patients. CASE
SUMMARY: We describe a case of a 46 year old HIV-infected male with smear-negative pulmonary tuberculosis, who had several visits to various lower level health centres and two admissions in a tertiary care hospital; however, the diagnosis of tuberculosis was only made several months later on GeneXpert testing that was performed under a research project.
CONCLUSION: GeneXpert facilitated identification of tuberculosis in an HIV positive patient in whom the diagnosis had been delayed when more widely available tests were used. Operational and cost-effectiveness studies are needed to provide evidence to policy makers in order to improve access to GeneXpert.

Entities:  

Keywords:  Tuberculosis; developing countries; molecular diagnostic techniques

Mesh:

Year:  2013        PMID: 24235959      PMCID: PMC3824516          DOI: 10.4314/ahs.v13i2.46

Source DB:  PubMed          Journal:  Afr Health Sci        ISSN: 1680-6905            Impact factor:   0.927


  9 in total

Review 1.  Xpert(®) MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope?

Authors:  Annelies Van Rie; Liesl Page-Shipp; Lesley Scott; Ian Sanne; Wendy Stevens
Journal:  Expert Rev Mol Diagn       Date:  2010-10       Impact factor: 5.225

Review 2.  Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance.

Authors:  Stephen D Lawn; Mark P Nicol
Journal:  Future Microbiol       Date:  2011-09       Impact factor: 3.165

3.  Evaluation of the analytical performance of the Xpert MTB/RIF assay.

Authors:  Robert Blakemore; Elizabeth Story; Danica Helb; JoAnn Kop; Padmapriya Banada; Michelle R Owens; Soumitesh Chakravorty; Martin Jones; David Alland
Journal:  J Clin Microbiol       Date:  2010-05-26       Impact factor: 5.948

Review 4.  Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes.

Authors:  Haileyesus Getahun; Mark Harrington; Rick O'Brien; Paul Nunn
Journal:  Lancet       Date:  2007-06-16       Impact factor: 79.321

5.  Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology.

Authors:  Danica Helb; Martin Jones; Elizabeth Story; Catharina Boehme; Ellen Wallace; Ken Ho; JoAnn Kop; Michelle R Owens; Richard Rodgers; Padmapriya Banada; Hassan Safi; Robert Blakemore; N T Ngoc Lan; Edward C Jones-López; Michael Levi; Michele Burday; Irene Ayakaka; Roy D Mugerwa; Bill McMillan; Emily Winn-Deen; Lee Christel; Peter Dailey; Mark D Perkins; David H Persing; David Alland
Journal:  J Clin Microbiol       Date:  2009-10-28       Impact factor: 5.948

6.  Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study.

Authors:  Catharina C Boehme; Mark P Nicol; Pamela Nabeta; Joy S Michael; Eduardo Gotuzzo; Rasim Tahirli; Ma Tarcela Gler; Robert Blakemore; William Worodria; Christen Gray; Laurence Huang; Tatiana Caceres; Rafail Mehdiyev; Lawrence Raymond; Andrew Whitelaw; Kalaiselvan Sagadevan; Heather Alexander; Heidi Albert; Frank Cobelens; Helen Cox; David Alland; Mark D Perkins
Journal:  Lancet       Date:  2011-04-18       Impact factor: 79.321

7.  Rapid and accurate detection of Mycobacterium tuberculosis in sputum samples by Cepheid Xpert MTB/RIF assay--a clinical validation study.

Authors:  Andrea Rachow; Alimuddin Zumla; Norbert Heinrich; Gabriel Rojas-Ponce; Bariki Mtafya; Klaus Reither; Elias N Ntinginya; Justin O'Grady; Jim Huggett; Keertan Dheda; Catharina Boehme; Mark Perkins; Elmar Saathoff; Michael Hoelscher
Journal:  PLoS One       Date:  2011-06-29       Impact factor: 3.240

8.  Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study.

Authors:  Stephen D Lawn; Sophie V Brooks; Katharina Kranzer; Mark P Nicol; Andrew Whitelaw; Monica Vogt; Linda-Gail Bekker; Robin Wood
Journal:  PLoS Med       Date:  2011-07-26       Impact factor: 11.069

Review 9.  Tuberculosis in antiretroviral treatment services in resource-limited settings: addressing the challenges of screening and diagnosis.

Authors:  Stephen D Lawn; Robin Wood
Journal:  J Infect Dis       Date:  2011-11-15       Impact factor: 5.226

  9 in total
  10 in total

1.  Nodding syndrome, infections and sexuality.

Authors:  James K Tumwine
Journal:  Afr Health Sci       Date:  2013-06       Impact factor: 0.927

2.  GeneXpert in the diagnosis of smear-negative PTB.

Authors:  Beuy Joob; Viroj Wiwanitkit
Journal:  Afr Health Sci       Date:  2014-06       Impact factor: 0.927

3.  Diagnosis of smear-negative pulmonary tuberculosis based on clinical signs in the Republic of Congo.

Authors:  Laure Stella Ghoma Linguissi; Christevy Jeannhey Vouvoungui; Pierre Poulain; Gaston Bango Essassa; Sylvie Kwedi; Francine Ntoumi
Journal:  BMC Res Notes       Date:  2015-12-18

4.  Evaluation of four molecular methods for the diagnosis of tuberculosis in pulmonary and blood samples from immunocompromised patients.

Authors:  Juliana Maria Azevedo de Lyra; Magda Maruza; Mirela Verza; Maria Madileuza Carneiro; Maria de Fátima Militão de Albuquerque; Maria Lúcia Rossetti; Ricardo Ximenes; Maria Cynthia Braga; Norma Lucena-Silva
Journal:  Mem Inst Oswaldo Cruz       Date:  2014-08-29       Impact factor: 2.743

5.  Performance of loop-mediated isothermal amplification assay in the diagnosis of pulmonary tuberculosis in a high prevalence TB/HIV rural setting in Uganda.

Authors:  Lydia Nakiyingi; Prossy Nakanwagi; Jessica Briggs; Tifu Agaba; Frank Mubiru; Mark Mugenyi; Willy Ssengooba; Moses L Joloba; Yukari C Manabe
Journal:  BMC Infect Dis       Date:  2018-02-21       Impact factor: 3.090

6.  Prevalence and patterns of rifampicin and isoniazid resistance conferring mutations in Mycobacterium tuberculosis isolates from Uganda.

Authors:  Edgar Kigozi; George W Kasule; Kenneth Musisi; Deus Lukoye; Samuel Kyobe; Fred Ashaba Katabazi; Eddie M Wampande; Moses L Joloba; David Patrick Kateete
Journal:  PLoS One       Date:  2018-05-30       Impact factor: 3.240

7.  Expressions of miR-29a, TNF-Α and Vascular Endothelial Growth Factor in Peripheral Blood of Pulmonary Tuberculosis Patients and Their Clinical Significance.

Authors:  Zhenyu Li; Chunlin Li; Ruri Bao; Zhidong Liu
Journal:  Iran J Public Health       Date:  2020-09       Impact factor: 1.429

8.  Predictors for MTB Culture-Positivity among HIV-Infected Smear-Negative Presumptive Tuberculosis Patients in Uganda: Application of New Tuberculosis Diagnostic Technology.

Authors:  Lydia Nakiyingi; Bareng A S Nonyane; Willy Ssengooba; Bruce J Kirenga; Damalie Nakanjako; Gloria Lubega; Pauline Byakika-Kibwika; Moses L Joloba; Jerry J Ellner; Susan E Dorman; Harriet Mayanja-Kizza; Yukari C Manabe
Journal:  PLoS One       Date:  2015-07-29       Impact factor: 3.240

9.  Role of GeneXpert MTB/Rif Assay in Diagnosing Tuberculosis in Pregnancy and Puerperium.

Authors:  Zaiyad G Habib; Farouq M Dayyab; Abdallah Sanda; Sirajo H Tambuwal; Mahmood M Dalhat; Hamza Muhammad; Garba Iliyasu; Ibrahim Nashabaru; Abdulrazaq G Habib
Journal:  Case Rep Infect Dis       Date:  2015-08-03

10.  Sequence analysis for detection of drug resistance in Mycobacterium tuberculosis complex isolates from the Central Region of Cameroon.

Authors:  Emmanuel Mouafo Tekwu; Larissa Kamgue Sidze; Jean-Paul Assam Assam; Jean-Claude Tedom; Serges Tchatchouang; Gaëlle Guiewi Makafe; Anne-Laure Tchokote Wetewale; Christopher Kuaban; Sara Eyangoh; Francine Ntoumi; Véronique N Penlap Beng; Matthias Frank
Journal:  BMC Microbiol       Date:  2014-05-03       Impact factor: 3.605

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.